Previous studies have pointed out that the treatment efficacy of Furmonertinib was better than Almonertinib in the subgroup of L858R in patients with EGFR T790M+ NSCLC (27, 28). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.